Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDRXNASDAQ:GEMPNASDAQ:OKURNASDAQ:RNTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$1.07-2.7%$1.34$1.01▼$41.50$39.10M1.21852,091 shs162,405 shsGEMPGemphire Therapeutics$0.75-0.3%$4.97$0.24▼$1.49$11.15M2.82127,174 shs53,481 shsOKUROnKure Therapeutics$2.65-7.0%$2.56$1.70▼$20.00$35.80M0.42111,140 shs164,916 shsRNTXRein Therapeutics$1.88-4.6%$1.84$1.35▼$4.40$41.65M1.350,636 shs83,340 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals-2.65%-4.35%-14.73%-42.11%+109,999,900.00%GEMPGemphire Therapeutics-2.90%+9.55%+7.39%-50.00%-81.28%OKUROnKure Therapeutics+0.71%-0.35%+54.89%-38.18%+284,999,900.00%RNTXRein Therapeutics+1.03%+1.03%+0.51%-1.50%+196,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDRXBiodexa Pharmaceuticals0.48 of 5 stars0.03.00.00.02.40.00.6GEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOKUROnKure Therapeutics3.347 of 5 stars3.70.00.00.03.32.51.3RNTXRein TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDRXBiodexa Pharmaceuticals 0.00N/AN/AN/AGEMPGemphire Therapeutics 0.00N/AN/AN/AOKUROnKure Therapeutics 3.33Buy$32.331,120.13% UpsideRNTXRein Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GEMP, RNTX, OKUR, and BDRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025OKUROnKure TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform3/18/2025OKUROnKure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDRXBiodexa Pharmaceuticals$83K471.11N/AN/A$42.56 per share0.03GEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/AOKUROnKure TherapeuticsN/AN/AN/AN/A$26.60 per shareN/ARNTXRein TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDRXBiodexa Pharmaceuticals-$7.66MN/A0.00N/AN/AN/AN/AN/AN/AGEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/AOKUROnKure Therapeutics-$77.39M-$5.26N/AN/AN/AN/A-51.17%-47.11%8/12/2025 (Estimated)RNTXRein Therapeutics-$15.73M-$2.86N/AN/AN/AN/A-74.08%-27.93%N/ALatest GEMP, RNTX, OKUR, and BDRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025RNTXRein Therapeutics-$0.21-$0.25-$0.04-$0.25N/AN/A5/6/2025Q1 2025OKUROnKure Therapeutics-$1.41-$1.19+$0.22-$1.19N/AN/A4/7/2025Q4 2024RNTXRein TherapeuticsN/A-$0.26N/A-$1.89N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDRXBiodexa Pharmaceuticals0.022.16N/AGEMPGemphire TherapeuticsN/A0.670.67OKUROnKure TherapeuticsN/A23.7123.71RNTXRein TherapeuticsN/A3.303.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDRXBiodexa Pharmaceuticals17.51%GEMPGemphire Therapeutics17.53%OKUROnKure Therapeutics90.98%RNTXRein Therapeutics90.89%Insider OwnershipCompanyInsider OwnershipBDRXBiodexa Pharmaceuticals0.34%GEMPGemphire Therapeutics22.70%OKUROnKure Therapeutics2.30%RNTXRein Therapeutics5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDRXBiodexa Pharmaceuticals2036.54 million36.42 millionNot OptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableOKUROnKure TherapeuticsN/A13.51 million2.75 millionN/ARNTXRein Therapeutics922.15 million20.56 millionN/AGEMP, RNTX, OKUR, and BDRX HeadlinesRecent News About These CompaniesFinancial Survey: Rein Therapeutics (RNTX) & Its RivalsJune 13 at 1:55 AM | americanbankingnews.comUS FDA puts on hold Rein Therapeutics' lung disease drug trialJune 12 at 5:18 PM | reuters.comRNTX Rein Therapeutics Inc.June 1, 2025 | seekingalpha.comRein Therapeutics, Inc.: Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 28, 2025 | finanznachrichten.deRein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 27, 2025 | prnewswire.comRein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International ConferenceMay 19, 2025 | prnewswire.comRein Therapeutics, Inc.: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16, 2025 | finanznachrichten.deRein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | prnewswire.comRein Therapeutics begins trial for idiopathic pulmonary fibrosis treatmentMay 13, 2025 | msn.comRein Therapeutics, Inc.: Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 12, 2025 | finanznachrichten.deRein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPFMay 12, 2025 | prnewswire.comRein Therapeutics to integrate Qureight’s platform in trial of IPF treatmentMay 2, 2025 | msn.comRein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPFMay 1, 2025 | prnewswire.comRein Therapeutics to Present at The Citizens Life Sciences Conference 2025April 30, 2025 | prnewswire.comRein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International ConferenceApril 28, 2025 | prnewswire.comRein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory DiseasesApril 23, 2025 | prnewswire.comRein Therapeutics reports IPF and PASC-F treatment progressApril 18, 2025 | uk.investing.comRein Therapeutics’ LTI-2355 peptide shows therapuetic potential in studyApril 16, 2025 | markets.businessinsider.comRein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-FApril 15, 2025 | prnewswire.comRein Therapeutics, Inc.: Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateApril 8, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGEMP, RNTX, OKUR, and BDRX Company DescriptionsBiodexa Pharmaceuticals NASDAQ:BDRX$1.07 -0.03 (-2.73%) Closing price 04:00 PM EasternExtended Trading$1.06 -0.01 (-0.47%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Gemphire Therapeutics NASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.OnKure Therapeutics NASDAQ:OKUR$2.65 -0.20 (-7.02%) Closing price 04:00 PM EasternExtended Trading$2.64 -0.02 (-0.57%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.Rein Therapeutics NASDAQ:RNTX$1.88 -0.09 (-4.57%) As of 04:00 PM EasternRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
